首页> 外文期刊>Infection and immunity >Murine antibody response to oral infection with live aroA recombinant Salmonella dublin vaccine strains expressing filamentous hemagglutinin antigen from Bordetella pertussis.
【24h】

Murine antibody response to oral infection with live aroA recombinant Salmonella dublin vaccine strains expressing filamentous hemagglutinin antigen from Bordetella pertussis.

机译:表达来自百日咳博德特氏菌的丝状血凝素抗原的活性aroA重组沙门氏菌都柏林疫苗株对口腔感染的鼠抗体反应。

获取原文
           

摘要

Two plasmids which express either nearly intact or truncated filamentous hemagglutinin (FHA) from Bordetella pertussis and which are marked with a tetracycline resistance (Tcr) gene were transformed into Salmonella dublin SL1438, an aroA deletion mutant intended for use as an attenuated oral vaccine against salmonellosis. These S. dublin recombinants, when fed to mice, induced serum immunoglobulin, immunoglobulin M (IgM), and sometimes IgA antibody responses to FHA and S. dublin. In addition, IgA antibodies against FHA were found in gut wash fluids. S. dublin carrying pDB2300, a multicopy plasmid encoding truncated FHA protein, induced a better antibody response than did S. dublin carrying pDB2000, a low-copy-number plasmid encoding full-sized FHA. Administration of tetracycline to mice enhanced the stability of recombinant plasmids, and tetracycline-treated mice developed higher anti-FHA titers. Although neither strain examined is suitable for use in a human oral vaccine, these data demonstrated that an immune response against B. pertussis FHA could be induced by oral administration of live attenuated recombinant strains of S. dublin and suggested that development of a live oral attenuated vaccine against pertussis may be possible.
机译:将表达百日咳博德特氏菌的几乎完整或截短的丝状血凝素(FHA)并标记有四环素抗性(Tcr)基因的两个质粒转化到沙门氏菌都柏林SL1438中,后者是aroA缺失突变体,旨在用作沙门氏菌病的减毒口服疫苗。当将这些都柏林链球菌重组体饲喂给小鼠时,会诱导血清免疫球蛋白,免疫球蛋白M(IgM),有时还会引起对FHA和都柏林链球菌的IgA抗体反应。此外,在肠道冲洗液中发现了针对FHA的IgA抗体。携带pDB2300(编码截短的FHA蛋白的多拷贝质粒)的都柏林链球菌比携带pDB2000(编码全尺寸FHA的低拷贝数质粒)的都柏林链球菌诱导更好的抗体反应。向小鼠施用四环素增强了重组质粒的稳定性,并且经四环素处理的小鼠表现出更高的抗FHA效价。尽管所检测的两种菌株都不适合用于人类口服疫苗,但这些数据表明,口服减毒的重组都柏林链球菌重组菌株可诱导针对百日咳博德特氏菌FHA的免疫反应,并提示口服减毒活菌的发展百日咳疫苗可能是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号